Galapagos N.V. GLPG
27.98 USD 0.00 (+0.00%)
Jun 4, 2026, 11:58 AM EDT
27.50 Day range 28.09
52-week range unavailable
- YTD
- -14.43%
- 1 year
- -3.08%
- Market cap
- 1.84B
- Profit margin
- 46.83%
- YTD return
- -14.43%
- 1-year return
- -3.08%
- Volume
- 2.38K
- Open
- 27.50
- Previous close
- 27.98
- Day's range
- 27.50 – 28.09
- Earnings date
- Aug 10, 2026
2Y -0.44 (-1.52%)
Key statistics
- Enterprise value
- 1.81B
- PEG ratio
- -0.10
- Price / sales
- 0.00
- Price / book
- 0.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 16.88%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 10, 2026
Expected Aug 10, 2026. Consensus EPS estimate 0.00.
Financials — quick view
GLPG Revenue — quarterly 8.06M
GLPG Net income — quarterly 14.49M
GLPG EPS — quarterly 0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2026 | Jun 30, 2026 | -0.96723 | — | — | — |
| May 6, 2026 | Mar 31, 2026 | -1.27 | 0.25 | +1.52 | +119.69% |
| Feb 23, 2026 | Dec 31, 2025 | 1.00 | 16.38 | +15.38 | +1,538.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.20 | -3.59 | -3.39 | -1,696.35% |
| Jul 23, 2025 | Jun 30, 2025 | -0.67 | -1.89 | -1.22 | -182.27% |
| Apr 23, 2025 | Mar 31, 2025 | -0.23 | -2.47 | -2.24 | -973.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 7, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 22, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 21, 2025 | Leerink Partners | up | Market Perform | Outperform |
| Feb 14, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jan 23, 2025 | Barclays | down | Equal-Weight | Underweight |
About Galapagos N.V.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- BE
- Employees
- 452
- Website
- lakefrontbio.com
News
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript 
Earnings Scheduled For May 6, 2026 
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update 
Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 
Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average – Time to Sell? 
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases 
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen 
Galapagos Announces Nomination of Gino Santini to its Board of Directors 
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur 
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings
Your note
Sign in to keep a note on GLPG — it syncs with the Stock Master app.